Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer
Authors
Borghaei, HosseinAlpaugh, Katherine
Hedlund, Gunnar
Forsberg, Goran
Langer, Corey J
Rogatko, Andre
Hawkins, Robert E
Dueland Svein
Lassen, Ulrik
Cohen, Roger B
Affiliation
Chrisite Research Centre, Manchester, United KingdomIssue Date
2009
Metadata
Show full item recordCitation
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. 2009, 27(25): 4116-4123 J Clin OncJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2008.20.2515Type
ArticleLanguage
enISSN
0732183X15277755
ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2008.20.2515